The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers.
ECL (ElectroChemiLuminescence) is Roche’s technology for immunoassay detection. Based on this technology and combined with well-designed, specific and sensitive immunoassays, Elecsys® delivers reliable results. The development of ECL immunoassay is based on the use of a ruthenium-complex and tripropylamine (TPA).
The chemiluminescence reaction for the detection of the reaction complex is initiated by applying a voltage to the sample solution, resulting in a precisely controlled reaction. ECL technology can accommodate many immunoassay principles while providing excellent performance.
Interleukin‑6 (IL‑6) is a pleiotropic cytokine and key mediator of the acute phase response induced by infection, inflammation, or trauma. Numerous cell types can produce IL‑6, but the most significant sources are macrophages and monocytes at the affected lesion. Following initial synthesis, IL‑6 is transported via the bloodstream to the liver, where it stimulates synthesis of the inflammatory acute phase proteins, such as C‑reactive protein (CRP). IL‑6 levels in blood rise within the first hour post inflammatory insult and peak after 2‑3 hours. The rapid increase in IL‑6 levels caused by inflammation and infection makes IL‑6 a useful clinical aid to guide diagnosis of acute inflammatory diseases, including sepsis. Elevations of IL‑6 in neonates are indicative of infection and can guide diagnosis of neonatal sepsis. Monitoring IL‑6 levels in critically ill patients provides prognostic information, as the magnitude of IL‑6 elevation correlates with the severity of inflammatory insult or disease. Post-operative IL‑6 levels can also be indicative of infection before presentations of clinical signs. Furthermore, elevated IL‑6 levels can be predictive of impending respiratory failure and need for mechanical ventilation in patients with COVID‑19. IL‑6 levels are also elevated in patients with chronic inflammatory disorders, such as rheumatoid arthritis, and can provide clinically useful information to guide patient management.
Source: IL-6 Method Sheet 09015604500V3.0, Method Sheet: 09015612500V5.0
